Favipiravir, an antiviral for COVID-19?

J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.

Authors

Eric A Coomes¹, Hourmazd Haghbayan^{2

3}

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Division of Cardiology, London Health Sciences Centre, Western University, London, Ontario, Canada.
³ Department of Social and Preventive Medicine, Université Laval, Québec, Québec, Canada.

No abstract available

MeSH terms

Amides / therapeutic use*
Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects
COVID-19
COVID-19 Drug Treatment
Clinical Trials as Topic
Coronavirus Infections / drug therapy*
Humans
Pandemics
Pneumonia, Viral / drug therapy*
Pyrazines / therapeutic use*
SARS-CoV-2

Substances

Amides
Antiviral Agents
Pyrazines
favipiravir